Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Dissecting the Mechanisms of Hepcidin and BMP-SMAD Pathway Regulation By FKBP12

Alessia Pagani, Mariateresa Pettinato, Alessandro Dulja, Silvia Colucci, Mariam Aghajan, Valeria Furiosi, Martina U. Muckenthaler, Shuling Guo, Antonella Nai, Laura Silvestri

Blood (2021) 138 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2021-152172

Published: 2021

Journal Articles

Rebalancing Iron Homeostasis and Erythropoiesis through Tfr2 Inhibition for Correction of Anemia in CKD

Violante Olivari, Maria Rosa Lidonnici, Mariam Aghajan, Mariateresa Pettinato, Simona Maria Di Modica, Alessia Pagani, Francesca Tiboni, Shuling Guo, Laura Silvestri, Giuliana Ferrari, Antonella Nai

Blood (2021) 138 (Supplement 1): 940.

https://doi.org/10.1182/blood-2021-148384

Published: 2021

Journal Articles

Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity

Blood (2020) 136 (17): 1968–1979.

https://doi.org/10.1182/blood.2019004719

Published: 2020

Includes: Supplemental data

Journal Articles

Targeting the BMP Receptor Inhibitor FKBP12 to Upregulate Hepcidin in Wild-Type and Hemojuvelin-Hemochromatosis Models

Mariateresa Pettinato, Mariam Aghajan, PhD, Violante Olivari, MSc, Alessandro Dulja, MSc, Antonella Nai, PhD, Jessica Bordini, PhD, Alessandro Campanella, PhD, Alessia Pagani, PhD, Shuling Guo, PhD, Clara Camaschella, MD, Laura Silvestri, PhD

Blood (2019) 134 (Supplement_1): 955.

https://doi.org/10.1182/blood-2019-126496

Published: 2019

Journal Articles

Inhibiting the Immunophilin FKBP12: A Potential Therapeutic Approach to Iron Overload/Low Hepcidin Disorders

Mariateresa Pettinato, MSc, Mariam Aghajan, Alessandro Dulja, Antonella Nai, PhD, Violante Olivari, Jessica Bordini, MSc, Alessandro Campanella, PhD, Alessia Pagani, PhD, Shuling Guo, Clara Camaschella, MD, Laura Silvestri, PhD

Blood (2018) 132 (Supplement 1): 2333.

https://doi.org/10.1182/blood-2018-99-118112

Published: 2018

Journal Articles

Transmembrane Protease, Serine 6 (TMPRSS6) Antisense Oligonucleotide (IONIS-TMPRSS6-L RX ) Reduces Plasma Iron Levels of Healthy Volunteers in a Phase 1 Clinical Study

Michael McCaleb, PhD, Jason Lickliter, MBBS, PhD, Andrew Dibble, PhD, Eugene Schneider, MD, Mariam Aghajan, Shuling Guo, Steve Hughes, MD MBA, Richard S Geary, PhD, Brett P. Monia, PhD

Blood (2018) 132 (Supplement 1): 3634.

https://doi.org/10.1182/blood-2018-99-115339

Published: 2018

Journal Articles

Correcting Non-Transfusion Dependent β-Thalassemia by Utilizing a Combined Therapy that Modulates EPO Activity by Limiting Erythroid Cellular Iron Intake

Carla Casu, Vania Lo Presti, Mariam Aghajan, Alison Liu, Kevin A Munoz, Emir O'Hara, Garry Neil, Reem Miari, Hagit Domev, Nir Shapir, Shuling Guo, Stefano Rivella

Blood (2018) 132 (Supplement 1): 164.

https://doi.org/10.1182/blood-2018-164

Published: 2018

Journal Articles

Potential Therapeutic Applications of Jak2 Inhibitors and Hif2a-ASO for the Treatment of β-Thalassemia Intermedia and Major

Carla Casu, Paraskevi Rea Oikonomidou, MD, Vania Lo Presti, Mariam Aghajan, PhD, Shuling Guo, PhD, Abdulmalik Osheiza, Luca Melchiori, Pedro Ramos, Stefano Rivella, PhD

Blood (2016) 128 (22): 1012.

https://doi.org/10.1182/blood.V128.22.1012.1012

Published: 2016

Journal Articles

Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia

Mariam Aghajan, PhD, Carla Casu, PhD, Vania lo Presti, Sheri Booten, Brett P. Monia, PhD, Stefano Rivella, PhD, Shuling Guo, PhD

Blood (2016) 128 (22): 1013.

https://doi.org/10.1182/blood.V128.22.1013.1013

Published: 2016

Journal Articles

Targeting TMPRSS6 Using Antisense Technology for the Treatment of Beta-Thalassemia

Shuling Guo, PhD, Mariam Aghajan, PhD, Carla Casu, PhD, Sara Gardenghi, PhD, Sheri Booten, Stefano Rivella, PhD, Brett P. Monia, PhD

Blood (2015) 126 (23): 753.

https://doi.org/10.1182/blood.V126.23.753.753

Published: 2015

Journal Articles

Combination of Tmprss6 -ASO and the Iron Chelator Deferiprone Improves Erythropoiesis and Reduces Iron Overload in a Mouse Model of Beta-Thalassemia

Carla Casu, PhD, Mariam Aghajan, PhD, Rea Oikonomidau, MD, Shuling Guo, PhD, Brett P. Monia, PhD, Stefano Rivella, PhD

Blood (2014) 124 (21): 4024.

https://doi.org/10.1182/blood.V124.21.4024.4024

Published: 2014

NARROW

Dissecting the Mechanisms of Hepcidin and BMP-SMAD Pathway Regulation By FKBP12

Rebalancing Iron Homeostasis and Erythropoiesis through Tfr2 Inhibition for Correction of Anemia in CKD

Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity

Targeting the BMP Receptor Inhibitor FKBP12 to Upregulate Hepcidin in Wild-Type and Hemojuvelin-Hemochromatosis Models

Inhibiting the Immunophilin FKBP12: A Potential Therapeutic Approach to Iron Overload/Low Hepcidin Disorders

Transmembrane Protease, Serine 6 (TMPRSS6) Antisense Oligonucleotide (IONIS-TMPRSS6-L RX ) Reduces Plasma Iron Levels of Healthy Volunteers in a Phase 1 Clinical Study

Correcting Non-Transfusion Dependent β-Thalassemia by Utilizing a Combined Therapy that Modulates EPO Activity by Limiting Erythroid Cellular Iron Intake

Potential Therapeutic Applications of Jak2 Inhibitors and Hif2a-ASO for the Treatment of β-Thalassemia Intermedia and Major

Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia

Targeting TMPRSS6 Using Antisense Technology for the Treatment of Beta-Thalassemia

Combination of Tmprss6 -ASO and the Iron Chelator Deferiprone Improves Erythropoiesis and Reduces Iron Overload in a Mouse Model of Beta-Thalassemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only